Last updated: June 12, 2024
Sponsor: Hong Daqing
Overall Status: Active - Recruiting
Phase
N/A
Condition
Anemia
Chronic Renal Anemia
Treatment
empirical therapy
Guiding treatment
Clinical Study ID
NCT06463236
01
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
① Age over 18 years old; ② Receive regular hemodialysis at least twice a week for at least 3 months, and have no plans to stop hemodialysis within 6 months since the start of the trial; ③ The patient voluntarily participated in this study.
Exclusion
Exclusion Criteria:
- Patients who have planned to undergo kidney transplantation or terminatehemodialysis during the study period; ② Previous history of bone marrowhematopoietic system diseases, such as combined myelodysplastic syndrome, multiplemyeloma, and other diseases; ③ Any known hereditary blood disease, such asthalassemia, sickle cell anemia, pure red blood cell aplasia, etc.; ④ Active orchronic gastrointestinal bleeding; ⑤ There was a severe infection within one weekprior to screening.
Study Design
Total Participants: 1296
Treatment Group(s): 2
Primary Treatment: empirical therapy
Phase:
Study Start date:
June 14, 2024
Estimated Completion Date:
August 31, 2025
Connect with a study center
Sichuan Provincial People's Hospital
Chengdu, Sichuan 610000
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.